NME Approval Decline Likely To Continue In 2002: Only Two Filed This Year
Executive Summary
FDA has received only two NDAs for new molecular entities so far in 2002, Office of New Drugs Director John Jenkins, MD, told UBS Warburg's specialty pharma conference in New York City June 6
You may also be interested in...
NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
FDA has received only 16 NDA submissions for new molecular entities thus far in fiscal 2002
NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
FDA has received only 16 NDA submissions for new molecular entities thus far in fiscal 2002
FDA Debates The “Slowdown”: Temple Sees No Sign Of Excess Caution
An analysis of recent drug approvals that took longer than one year shows no indications of a more conservative attitude by FDA, Office of Medical Policy Director Robert Temple, MD, told the Food & Drug Law Institute conference April 17 in Washington, D.C